NEW YORK (GenomeWeb) – The Genome Institute of Singapore announced today that it has agreed to work with Singapore-based firm Pyrobett to develop novel molecular diagnostics based on pyrosequencing technology.

Pyrobett, which is a joint venture between Qiagen and life sciences instruments manufacturer BMS, has developed a pyrosequencing platform that will be used by the partners in a joint laboratory to create and validate molecular diagnostics assays, including bacterial and viral genotyping, the detection of mutations associated with drug resistance, and cancer detection.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: full CRISPR locus integration complex structure, and more.

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

Sponsored by

This webinar will address improvements in the library prep workflow for small RNA sequencing in serum and plasma.